Sep22019UncategorizedCategory: UncategorizedBy Charlotte Maddalena2 September 2019Leave a comment Author: Charlotte Maddalena Post navigationPreviousPrevious post:Signature of a memorandum of understanding for the acquisition of Mathym SASNextNext post:Two new projects supported by our FoundationRelated PostsORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma10 December 2019ORPHELIA Pharma recrute un/une Assistant(e) administrative, commercial(e) et comptable9 December 2019ORPHELIA Pharma Recrute un/une Medical Science Liaison France et Europe9 December 2019ORPHELIA Pharma recrute un/une Responsable marchés publics France et Europe9 December 2019Newsletter november 20194 December 2019Two new projects supported by our Foundation4 December 2019
ORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma10 December 2019
ORPHELIA Pharma recrute un/une Assistant(e) administrative, commercial(e) et comptable9 December 2019
